<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173117</url>
  </required_header>
  <id_info>
    <org_study_id>0699</org_study_id>
    <nct_id>NCT04173117</nct_id>
  </id_info>
  <brief_title>Feasibility of Low Energy Diet in HFpEF and Type 2 Diabetes</brief_title>
  <acronym>ALLEVIATE</acronym>
  <official_title>A Low-energy Meal Replacement Plan for Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leicester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leicester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open, Single arm intervention, feasibility study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aims of the proposed feasibility study are to assess whether a low-energy meal&#xD;
      replacement plan (MRP) in patients with HFpEF and T2D:&#xD;
&#xD;
      1. Is acceptable to an older, co-morbid, multi-ethnic population&#xD;
&#xD;
      The secondary objectives are to assess whether a low-energy MRP in patients with HFpEF and&#xD;
      T2D may be:&#xD;
&#xD;
        1. associated with improved symptoms&#xD;
&#xD;
        2. likely to lead to favourable cardiovascular reverse remodelling&#xD;
&#xD;
        3. likely to improve functional capacity and quality of life&#xD;
&#xD;
        4. associated with favourable reductions in cardiovascular biomarkers&#xD;
&#xD;
        5. associated with increased physical activity&#xD;
&#xD;
        6. associated with favourable cardiovascular outcomes&#xD;
&#xD;
      All patients will undergo the following assessments at baseline, 12-weeks and 12 months&#xD;
      (following MRP):&#xD;
&#xD;
        1. Anthropometry: height, weight, BMI.&#xD;
&#xD;
        2. Haemodynamics: resting heart rate and blood pressure.&#xD;
&#xD;
        3. 6-minute walk test +/- cardiopulmonary exercise test (if able to perform)&#xD;
&#xD;
        4. CMR: contrast enhanced, stress perfusion CMR&#xD;
&#xD;
        5. MLWHFQ&#xD;
&#xD;
        6. WHODAS 2.0 (12-item version)&#xD;
&#xD;
        7. Fasting blood test: full blood count, urea and electrolytes, HbA1c, fasting glucose,&#xD;
           BNP, high-sensitivity troponin I, insulin and C-peptide. Plasma (≈35mL) will be stored&#xD;
           for future biomarker analysis including metabolomics.&#xD;
&#xD;
        8. Urinalysis for proteinuria and urine protein/creatinine ratio.&#xD;
&#xD;
        9. Body composition; dual-energy X-ray absorptiometry (DEXA) scanning.&#xD;
&#xD;
      12. At the end of the 12-week intervention, participants will be invited to a semi-structured&#xD;
      interview to explore qualitative aspects of the study to guide future trial design.&#xD;
&#xD;
      13. At 12 months attendance at cardiac rehabilitation will be reviewed.&#xD;
&#xD;
      The MRP provided by Cambridge Weight Plan® contains ~810 kcal/day (30% protein, 50%&#xD;
      carbohydrate, 20% fat). The diet will be stopped, and a maintenance diet re-introduced once&#xD;
      50% excess body weight has been lost, or by 12 weeks, whichever comes first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Low energy meal replacement plan for 12 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment and retention rates</measure>
    <time_frame>16 weeks</time_frame>
    <description>The number of people approached, recruited and retained</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in 6 minute walk test pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Meters walked within 6 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in cardiopulmonary exercise test (peak VO2) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>exercise test on a static bike using minute by minute ventilatory gas analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in LV remodelling (indexed LV mass) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>CMR measures of cardiac geometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in LV function pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>CMR measures of cardiac function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in E/A ratio pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Standard clinical echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in E (cm/s) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Standard clinical echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in MV deceleration time (ms) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Standard clinical echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in A (cm/s) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Standard clinical echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Septal e' pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Standard clinical echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Lateral e' pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Standard clinical echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Septal E/e' pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Standard clinical echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Lateral E/e' pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Standard clinical echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Average E/e' pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Standard clinical echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in LA volume indexed pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Standard clinical echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in TR jet velocity (m/s) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Standard clinical echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in BMI pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Weighing scales and stadiometer measurement (Kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Bone Mineral Density (g/cm2) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>DEXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Total Fat mass (g) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>DEXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Total tissue fat (%) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>DEXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in visceral adipose tissue mass (g) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>DEXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in visceral adipose tissue volume (cm3) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>DEXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Total lean body mass (g) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>DEXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in World Health Organisation Disability Schedule (WHODAS 2.0) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Scale 0 - 48 with lower scores indicating better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Medical Research Council Dyspnoea Scale pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>scale 1 - 5 with lower scores indicating better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Minnesota Living with heart Failure Questionnaire pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Scale 0 - 105 with lower scores indicating better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Fasting Glucose (mmol/L) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in HbA1c (%) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in HbA1c (mmol/mol) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in B-type (ng/L) natriuretic peptide pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in hs-troponin (ng/L) natriuretic peptide pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in CRP (mg/L), natriuretic peptide pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in albumin concentration pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in albumin/creatinine ratio concentration pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in sodium (mmol/L) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in potassium (mmol/L) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Urea (mmol/L) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in creatinine (umol/L) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in eGFR (ml/min) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in hsTnl(ng/L) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in hALT (iu/L) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in ALP (iu/L)pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in LDL (mmol/L) pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in kidney function pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood analysis for eGFR (ml/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in liver function pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Blood analysis for ALP (iu/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the levels of physical activity pre- and post intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Objectively measured with an accelerometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac rehabilitation uptake</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of participants who were offered and attended cardiac rehabilitation following completion of the intervention (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants who experience any Major Adverse Cardiovascular Events (MACE)</measure>
    <time_frame>12 weeks</time_frame>
    <description>At any point during the study if a participant experiences a major cardiovascular event this will be recorded and reported to sponsor in line with handling serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Dietary Exposure</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low energy meal replacement plan 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low energy meal replacement plan (12 weeks)</intervention_name>
    <description>Low energy meal replacement plan (12 weeks)</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Established T2D (HbA1c ≥6.5%, duration &gt;3months)&#xD;
&#xD;
          -  Obesity (BMI ≥30 or ≥27 kg/m2 if black/south Asian ethnicity)&#xD;
&#xD;
          -  Symptoms limiting exercise capacity in normal daily activities (dyspnoea or fatigue)&#xD;
             or an established diagnosis of HF&#xD;
&#xD;
          -  Diagnosis of HFpEF in accordance with European Society of Cardiology criteria: LV EF&#xD;
             &gt;50% with objective evidence of cardiac structural or functional alterations (LV&#xD;
             hypertrophy (≥12mm); LV mass index ≥115g/m2 for males and ≥95g/m2 for females; E/e'&#xD;
             ≥13 and a mean e' septal and lateral wall &lt;9 cm/s; left atrial volume index &gt;34mL/m2&#xD;
             or reduced global longitudinal strain (&gt;-18%); elevated levels of natriuretic peptides&#xD;
             (B-type natriuretic peptide &gt;35pg/mL and/or NT-pro B-type natriuretic peptide&#xD;
             &gt;125pg/mL))&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling to undertake MRP (low energy diet)&#xD;
&#xD;
          -  HBa1c &gt;10%&#xD;
&#xD;
          -  Diabetes duration &gt;12 years&#xD;
&#xD;
          -  High-dose insulin requirement: either on full basal-bolus insulin regime or insulin&#xD;
             requirement &gt;1U/kg/day&#xD;
&#xD;
          -  Have been on insulin treatment &gt;10 years&#xD;
&#xD;
          -  Current treatment with anti-obesity drugs&#xD;
&#xD;
          -  Diagnosed eating disorder or purging&#xD;
&#xD;
          -  Weight loss &gt; 5kg in preceding 3 months (unless related to hospitalisation for HF)&#xD;
&#xD;
          -  Absolute contraindications to MRI&#xD;
&#xD;
          -  Severe renal impairment eGFR&lt;30ml/min/m2&#xD;
&#xD;
          -  Myocardial infarction within preceding 6 months&#xD;
&#xD;
          -  History of substance abuse&#xD;
&#xD;
          -  Cancer undergoing active treatment&#xD;
&#xD;
          -  Unable to consent due to lack of mental capacity&#xD;
&#xD;
          -  Pregnancy/considering pregnancy&#xD;
&#xD;
          -  People unable to perform activities of daily living independently or unable attend for&#xD;
             clinical appointments without a carer/attendant&#xD;
&#xD;
          -  Unable to read/understand English sufficiently to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Grace Walters</last_name>
    <phone>01162044723</phone>
    <email>gwmw1@leicester.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emer M Brady</last_name>
    <phone>01162044723</phone>
    <email>emb29@le.acuk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Research Centre (Glenfield Hospital)</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Walters, PhD</last_name>
      <phone>01162044723</phone>
      <email>gwmw1@leicester.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Emer Brady, PhD</last_name>
      <phone>01162044723</phone>
      <email>emb29@le.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

